U.S. Logistics Stock News

NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

TG Therapeutics (TGTX) Earnings Spark Debate As 72.6% Net Margin Defies Forecast Narratives

Intro TG Therapeutics (TGTX) just closed out FY 2025 with Q4 revenue of US$192.6 million and basic EPS of US$0.16, alongside trailing twelve month revenue of US$616.3 million and EPS of US$3.10. Over the past couple of years, the company has reported revenue increasing from US$83.9 million in Q3 2024 to US$192.6 million in Q4 2025. Quarterly basic EPS has ranged from US$0.03 in Q1 2025 to US$2.69 in Q3 2025 and US$0.16 in the latest quarter, framing this release as a check-in on how durable...
NasdaqGS:SNDX
NasdaqGS:SNDXBiotechs

A Look At Syndax Pharmaceuticals (SNDX) Valuation After Q4 Revenue Beat And Wider Loss

Syndax Pharmaceuticals (SNDX) just reported Q4 2025 results that paired revenue ahead of expectations with a wider loss, as Revuforj net revenue grew 38% and Niktimvo sales continued to build. See our latest analysis for Syndax Pharmaceuticals. At a share price of US$20.67, Syndax has seen a 4.29% 90 day share price return and a 35.27% total shareholder return over the past year, suggesting momentum has been building despite some recent short term softness. If this update on a cancer focused...
NYSE:PRG
NYSE:PRGConsumer Finance

PROG Holdings Raises Dividend While Reshaping Business After Partner Fallout

PROG Holdings (NYSE:PRG) announced a 7.7% increase in its quarterly dividend, signaling confidence in returning cash to shareholders. The company is managing revenue pressure tied to a weaker retail backdrop and the bankruptcy of a major partner. Management has tightened Progressive Leasing criteria and is leaning more on its buy now, pay later platform and recent acquisitions. PROG Holdings enters this phase of corporate change with its shares at $36.83 and a mixed return profile. The...
NasdaqGS:AVAV
NasdaqGS:AVAVAerospace & Defense

A Look At AeroVironment (AVAV) Valuation After The US$186 Million Switchblade Contract Win

AeroVironment (AVAV) drew fresh investor focus after securing a US$186 million delivery order from the U.S. Army for its next-generation Switchblade 600 Block 2 and 300 Block 20 loitering munitions. See our latest analysis for AeroVironment. Despite the new Army order and recent headlines around the BlueHalo acquisition and the CFO transition, AeroVironment’s 30 day share price return of 16.14% and 90 day return of 7.10% contrast with a 1 year total shareholder return of 70.96% and a roughly...
NYSE:BEN
NYSE:BENCapital Markets

Assessing Franklin Resources (BEN) Valuation After Its Latest Earnings Surprise

Franklin Resources (BEN) has been back on investors’ radar after its latest quarterly report showed earnings per share coming in ahead of analyst expectations. This has prompted fresh interest in how the asset manager is currently valued. See our latest analysis for Franklin Resources. The recent earnings surprise has come alongside a clear shift in sentiment around the share price, with Franklin Resources posting a 21.43% 90 day share price return and a 46.49% 1 year total shareholder...
NYSE:LPX
NYSE:LPXForestry

A Look At Louisiana-Pacific (LPX) Valuation As Mixed Returns Temper Recent Share Moves

Why Louisiana-Pacific Is On Investors’ Radar Today Louisiana-Pacific (LPX) is drawing attention after recent share moves, with the stock up about 1.4% over the past day but showing mixed performance over the past week and month. See our latest analysis for Louisiana-Pacific. The 1-day share price return of 1.45% comes after a softer patch. The 30-day share price return of 5.10% and 1-year total shareholder return decline of 14.97% signal that shorter term momentum has cooled, despite stronger...
NYSE:TMO
NYSE:TMOLife Sciences

Thermo Fisher’s TacroType Test Adds Precision Medicine Angle To TMO Story

Thermo Fisher Scientific (NYSE:TMO) has launched its TacroType Pharmacogenetic Test for transplant patients. The test is designed to help clinicians personalize tacrolimus dosing using a patient’s genetic profile. This product aims to support more tailored transplant care and potentially improve post transplant management. Thermo Fisher Scientific enters this launch with its shares at $520.12 and a value score of 4, along with mixed recent returns. The stock is up 1.0% over the past week,...
NasdaqGS:CDNL
NasdaqGS:CDNLConstruction

Is It Too Late To Consider Cardinal Infrastructure Group (CDNL) After A 46% Year To Date Rise?

If you are wondering whether Cardinal Infrastructure Group is priced attractively today, you are not alone. The stock has been on many investors' watchlists as questions around its fair value grow louder. The share price sits at US$33.05, with returns of 2.5% over the last 7 days, 19.2% over the past 30 days, and 46.1% year to date. This has sharpened interest in what is actually built into the current valuation. Recent coverage has focused on Cardinal Infrastructure Group's role in the...
NYSE:WCN
NYSE:WCNCommercial Services

A Look At Waste Connections (WCN) Valuation As Returns Cool And Growth Appears Priced In

Recent performance snapshot for Waste Connections With no single headline event driving attention to Waste Connections (WCN) today, investors may be focusing on how the stock’s recent returns compare with its longer term track record and current business scale. The share price is roughly flat over the past month and shows a return of about 4% decline over the past 3 months, while year to date performance reflects about 3% decline. Over 1 year, total return stands near 8% decline, set against...
NasdaqGS:CROX
NasdaqGS:CROXLuxury

Is Crocs (CROX) Pricing Look Attractive After Recent Share Price Swings?

If you are wondering whether Crocs at around US$92.70 is a bargain or a trap, you are not alone. The stock has attracted a lot of attention from investors trying to work out what a fair price looks like. Recently, Crocs has had mixed share price returns, with a 3.9% decline over the last 7 days, a 10.2% gain over the last 30 days, a 6.6% gain year to date, an 8.1% decline over 1 year, a 26.0% decline over 3 years, and a 23.3% gain over 5 years. These moves have played out alongside ongoing...
NYSE:RCUS
NYSE:RCUSBiotechs

Arcus Biosciences (RCUS) Posts US$106 Million Q4 Loss Reinforcing Bearish Profitability Narratives

Arcus Biosciences (RCUS) has wrapped up FY 2025 with fourth quarter revenue of US$33 million and a basic EPS loss of US$0.89, alongside a net loss of US$106 million. This sets a clear backdrop of solid top line contributions paired with continued negative earnings. The company has reported quarterly revenue of US$26 million in Q4 2024, US$28 million in Q1 2025, US$160 million in Q2 2025, US$26 million in Q3 2025 and US$33 million in Q4 2025, while EPS has remained in loss territory across...
NYSE:VYX
NYSE:VYXSoftware

Assessing NCR Voyix (VYX) Valuation After Strong Q4 Results And New 7 Eleven Philippines Contract

NCR Voyix (VYX) has just paired a profitable fourth quarter with fresh 2026 guidance and a new 7-Eleven Philippines win, giving investors a clearer view of its software led platform push. See our latest analysis for NCR Voyix. Despite the new 7-Eleven Philippines contract, a buyback authorization increase to US$300 million and 2026 guidance, NCR Voyix’s recent momentum has been weak. Its latest 1-year total shareholder return of 26.95% decline and 5-year total shareholder return of 62.23%...
NYSE:DT
NYSE:DTSoftware

A Look At Dynatrace (DT) Valuation After Positive Analyst Attention And AWS AI Observability Milestones

Analyst interest and executive commentary put Dynatrace in focus Dynatrace (DT) is back on investor radars after a cluster of upbeat analyst views and recent executive interviews linked to new milestones with AWS and its AI powered observability platform. See our latest analysis for Dynatrace. Despite the recent analyst attention and AWS related milestones, Dynatrace’s share price return over the past 30 and 90 days has been negative, and its 1 year total shareholder return of a 36.6% decline...
NasdaqGS:ROP
NasdaqGS:ROPSoftware

A Look At Roper Technologies (ROP) Valuation After Its 2025 10 K And Software Focused Acquisitions

Roper Technologies (ROP) is back in focus after its 2025 10-K highlighted strong growth tied to software and technology enabled products, supported by nine acquisitions, including CentralReach and Subsplash. See our latest analysis for Roper Technologies. At a share price of US$352.15, Roper’s short term momentum has picked up with a 1 week share price return of 6.1% after its 2025 10 K and recent dividend affirmation. However, this follows a 90 day share price return decline of 21.1% and a 1...
NasdaqGS:CSCO
NasdaqGS:CSCOCommunications

Cisco’s Secure AI Factory Adds New Angle To Fairly Valued Stock

Cisco Systems (NasdaqGS:CSCO) has launched Australia's first Secure AI Factory in partnership with SharonAI Holdings and NVIDIA. The new facility is designed to support sovereign AI capabilities and secure national data processing. The initiative targets Australian enterprise and public sector customers seeking country level AI infrastructure. Cisco Systems, trading at around $78.1, is adding a new piece to its AI story with this Secure AI Factory launch in Australia. The company has seen a...
NasdaqGS:SAIC
NasdaqGS:SAICProfessional Services

A Look At Science Applications International (SAIC) Valuation After New US$95 Million Federal IT Contract

Science Applications International (SAIC) has just secured a new US$95 million contract with the U.S. Government Accountability Office to modernize the Technical Information Services program, putting its federal IT capabilities in sharper focus for investors. See our latest analysis for Science Applications International. The contract news arrives after a volatile stretch, with the 1-day share price return of 5.66% contrasting with a 30-day share price return decline of 11.57% and a 1-year...
NYSE:SCCO
NYSE:SCCOMetals and Mining

Southern Copper (SCCO) Is Up 11.1% After Long-Term Expansion Plan Offsets Softer Output Outlook - What's Changed

Southern Copper recently reported slightly lower 2025 copper production and trimmed its 2026 outlook due to lower ore grades at Peruvian operations, while outlining nearly US$19.90 billion of long-term growth projects aimed at lifting annual output by 2035. At the same time, the company has kept earnings momentum intact, with consistent estimate beats and strong technical strength suggesting ongoing institutional interest despite nearer-term operational constraints. Now we’ll examine how...
NYSE:BAH
NYSE:BAHProfessional Services

A Look At Booz Allen Hamilton (BAH) Valuation After Tariff Uncertainty And Civil Revenue Headwinds

The Trump administration’s new global tariffs pushed trade policy back into focus this week, coinciding with Booz Allen Hamilton Holding (BAH) working through civil revenue pressure, its worst public market drawdown, and steadier defense and national security demand. See our latest analysis for Booz Allen Hamilton Holding. Recent events, from contract cancellations after a major data breach to the latest tariff headlines and civil revenue pressure, have contributed to a 1 year total...
NasdaqGS:MRNA
NasdaqGS:MRNABiotechs

Moderna (MRNA) Valuation Check As FDA Reconsiders Flu Shot And EU Backs Combined Vaccine

Moderna (MRNA) is back in the regulatory spotlight after the FDA reversed an earlier refusal and agreed to review its mRNA seasonal flu vaccine, while European regulators backed its combined flu and COVID-19 shot. See our latest analysis for Moderna. That regulatory reset has come alongside strong share price momentum, with a 13.77% 1 month share price return, a 99.04% 3 month share price return and a 67.56% year to date share price return at a last close of US$51.71. However, the 3 year...
NasdaqGS:INTR
NasdaqGS:INTRBanks

Is It Too Late To Consider Inter & Co (INTR) After Recent Pullback In The Share Price

Wondering whether Inter & Co at around US$8.89 still offers value or if most of the opportunity is already priced in? This article focuses on what the numbers say about that question. The stock has had mixed recent moves, with a 1.7% decline over the last 7 days and a 10.9% decline over the last 30 days, yet it still sits on a 5.2% year to date return and a 69.5% return over the past year, alongside a very large 3 year return of roughly 4x. Recent coverage around Inter & Co has centered on...
NasdaqGS:DMLP
NasdaqGS:DMLPOil and Gas

A Look At Dorchester Minerals (DMLP) Valuation After Mixed Recent Performance And A Wide DCF Gap

Recent performance and what it might signal Dorchester Minerals (DMLP) has drawn fresh attention after recent price moves, with the unit price around $25.50 and mixed returns across different periods, including gains over the past 3 months but a 1 year total return decline. See our latest analysis for Dorchester Minerals. At a share price of about $25.50, Dorchester Minerals has recently seen a 16.2% 90 day share price return, while the 1 year total shareholder return shows an 8.8% decline...
NasdaqGS:WBD
NasdaqGS:WBDEntertainment

Reassessing Warner Bros. Discovery (WBD) Valuation As Contrasting Fair Value Views Emerge

Warner Bros. Discovery overview and recent stock context Warner Bros. Discovery (WBD) continues to attract investor attention as its share price sits at $28.80, with recent returns of 0.2% over the past 3 months and 1.51x over the past year. See our latest analysis for Warner Bros. Discovery. With the share price at $28.80, Warner Bros. Discovery has logged a 20% 90 day share price return and a very large 1 year total shareholder return, which suggests momentum has been building as investors...
NYSE:DOC
NYSE:DOCHealth Care REITs

Is Healthpeak’s Janus Living Senior Housing Spinout Altering The Investment Case For DOC?

Healthpeak Properties has advanced its plan to spin out its senior housing portfolio via the Janus Living IPO, filing a preliminary prospectus for class A-1 shares that are expected to list on the NYSE under the ticker JAN. The move, alongside CEO Scott Brinker's recent presentation at the Citi 2026 Global Property CEO Conference, highlights how Healthpeak is reshaping its portfolio focus and communicating its long-term vision to investors. Next, we'll examine how the planned Janus Living...
NasdaqGS:BKR
NasdaqGS:BKREnergy Services

Should Baker Hughes’ AI Data Center Power Deal Expansion Require Action From Baker Hughes (BKR) Investors?

In February 2026, Baker Hughes announced it would supply 25 BRUSH Power Generation electric generators, Automatic Voltage Regulators and cubicles to Boom Supersonic, expanding a prior 2025 agreement to support 1.3 GW of onsite power capacity for AI-focused data centers through deliveries scheduled from mid-2026 to 2028. This contract underscores Baker Hughes’ push into higher-value Industrial & Energy Technology solutions, tying its generator portfolio directly to the fast-growing AI data...